2017年ESMO结直肠癌领域研究进展解读——基础应用篇  

Highlights in the field of colorectal cancer comes from 2017 ESMO congress——basic application

作　　者：隋红[1] Sui Hong(Medical Department,Harbin Medical University Cancer Hospital,Harbin 150040,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院内二科,150040

出　　处：《中华结直肠疾病电子杂志》2018年第2期120-124,共5页Chinese Journal of Colorectal Diseases(Electronic Edition)

基　　金：国家自然科学基金青年基金资助项目(No.81201876);黑龙江省青年自然基金项目(No.QC2012C011);黑龙江省博士后基金项目(No.LBH-Z12210);吴阶平医学基金会临床基金项目(No.320.6750.15255)

摘　　要：European Society For Medical Oncology(ESMO)大会是欧洲最具影响力的肿瘤专家年度会议。2017年ESMO大会于2017年9月8日至12日在西班牙马德里举行,大会将癌症研究人员和临床医生聚集在一起,开展合作,交流思想,促进实验室到临床以及从临床到实验室的相互转化。现将会议期间有关结直肠癌领域临床前沿及引申的基础研究诸如免疫治疗优化获益人群、转化研究、肿瘤标记物、肿瘤基因型和表型的变化与疾病预后以及治疗方式和/或药物选择的相关性、结直肠癌新靶点等做一简要梳理。The European Society For Medical Oncology(ESMO)congress is the most influential annual meeting for oncology professionals in Europe.The 2017 ESMO Congress was held in Madrid,Spain from 8th to 12th September 2017 and brought cancer researchers and clinicians together to enable collaboration and exchange their ideas from the laboratory to the bedside and back.Here,development in basic research of colorectal cancer will be summarized including following points such as optimizing the beneficiaries for immunotherapy,translational research,tumor bio-marker,genotypic and phenotypic alteration in cancer related to disease prognosis,manipulation and/or drug choice,therapeutic target in mCRC treatment.

关 键 词：结直肠肿瘤 免疫治疗 靶向治疗 MSI EPH A2 

分 类 号：R735.34[医药卫生—肿瘤]